Kazia to present final data from paxalisib phase II study as ASCO

Posted in Uncategorized

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, today announced that final data from its phase II study of paxalisib in patients with newly diagnosed glioblastoma will be the subject of a poster presentation at the upcoming Annual Meeting of the American Society for Clinical Oncology (ASCO).

The ASCO Annual Meeting will take place virtually and in person from 3-7 June 2022and will be held in Chicago, IL.

Abstracts from the meeting are expected to be released from 5pm, ET, on 26 May 2022, and the poster will be made available by ASCO and via the Kazia website shortly after presentation.


Title: Paxalisib in patients with newly diagnosed glioblastoma with unmethylated MGMT promoter status: Final phase 2 study results.
Date and Time: Sunday, 5 June 20228am11am, CDT
Session: Central Nervous System Tumors
Abstract ID: 2047